Pacific Biosciences of California (NASDAQ: PACB) and Reshape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
This is a summary of recent ratings for Pacific Biosciences of California and Reshape Lifesciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||1||0||2.33|
Insider and Institutional Ownership
60.3% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 20.8% of Reshape Lifesciences shares are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 26.4% of Reshape Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Pacific Biosciences of California and Reshape Lifesciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$93.47 million||3.90||-$92.18 million||($0.89)||-3.13|
|Reshape Lifesciences||$790,000.00||56.13||-$23.36 million||($5.90)||-0.25|
Reshape Lifesciences has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Reshape Lifesciences, indicating that it is currently the more affordable of the two stocks.
This table compares Pacific Biosciences of California and Reshape Lifesciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-98.63%||-98.98%||-59.92%|
Risk and Volatility
Pacific Biosciences of California has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Reshape Lifesciences has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500.
Reshape Lifesciences beats Pacific Biosciences of California on 7 of the 13 factors compared between the two stocks.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Reshape Lifesciences Company Profile
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.